Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | NT5E | P21589 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | TOP2A | P11388 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | PTGES | O14684 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.53 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betulone SCHEMBL14374402 | 1.00 | GPBAR1 (0.73) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betulone SCHEMBL13910773 | 1.00 | GPBAR1 (0.73) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betulone SCHEMBL5448679 | 1.00 | GPBAR1 (0.73) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betulone SCHEMBL22010112 | 1.00 | GPBAR1 (0.73) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| Betulone SCHEMBL12363687 | 1.00 | GPBAR1 (0.73) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL14666445 | 0.93 | GPBAR1 (0.74) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL13910793 | 0.92 | GPBAR1 (0.62) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL13910765 | 0.92 | GPBAR1 (0.62) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL13910818 | 0.92 | GPBAR1 (0.61) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 | |
| SCHEMBL13910804 | 0.91 | LMNA (0.61) | GPBAR1LMNANT5ESMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207333-B2 | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | REGENERA PHARMA LTD. (IL) | 2021-12-28 | — | — | US | disclosed |
| US-11173164-B2 | Compositions comprising triterpenoids | REGENERA PHARMA LTD. (IL) | 2021-11-16 | — | — | US | disclosed |
| EP-3352742-B1 | COMPOSITIONS COMPRISING TRITERPENOIDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | REGENERA PHARMA LTD (IL) | 2021-11-03 | — | — | EP | disclosed |
| US-11083736-B2 | Compositions comprising triterpenoids | REGENERA PHARMA LTD. (IL) | 2021-08-10 | — | — | US | disclosed |
| US-20200155569-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| US-20190314389-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2019-10-17 | — | — | US | disclosed |
| US-20190224217-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY | REGENERA PHARMA LTD. (IL) | 2019-07-25 | — | — | US | disclosed |
| US-20190209582-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2019-07-11 | — | — | US | disclosed |
| US-10285996-B2 | Compositions comprising triterpenoids | REGENERA PHARMA LTD. (IL) | 2019-05-14 | — | — | US | disclosed |
| WO-2017051423-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017051422-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | REGENERA PHARMA LTD. (IL) | 2017-03-30 | — | — | WO | disclosed |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | Valition teknillinen tutikimuskeskus (FI) | 2010-10-28 | — | — | US | disclosed |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | Valition teknillinen tutikimuskeskus (FI) | 2010-10-28 | — | — | US | disclosed |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-05 | — | — | US | disclosed |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-08-05 | — | — | US | disclosed |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-07-29 | — | — | US | disclosed |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207333-B2 | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy | AQP4, CYP27A1, PMP22 | GPBAR1 445/4885LMNA 3274/4885NT5E 530/4885 |
| US-11173164-B2 | Compositions comprising triterpenoids | PARK7, SNCA, APP | GPBAR1 313/4885LMNA 3158/4885NT5E 1973/4885 |
| US-20190209582-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | PARK7, SNCA, APP | GPBAR1 313/4885LMNA 3158/4885NT5E 1973/4885 |
| US-20200155569-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | PARK7, SNCA, APP | GPBAR1 313/4885LMNA 3158/4885NT5E 1973/4885 |
| US-20190224217-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY | AQP4, CYP27A1, PMP22 | GPBAR1 445/4885LMNA 3274/4885NT5E 530/4885 |
| US-20190314389-A1 | COMPOSITIONS COMPRISING TRITERPENOIDS | CYP27A1, CYP11B2, CYP11B1 | GPBAR1 138/4885LMNA 1750/4885NT5E 1482/4885 |
| US-11083736-B2 | Compositions comprising triterpenoids | CYP27A1, CYP11B2, CYP11B1 | GPBAR1 138/4885LMNA 1750/4885NT5E 1482/4885 |
| US-10285996-B2 | Compositions comprising triterpenoids | PARK7, SNCA, APP | GPBAR1 313/4885LMNA 3158/4885NT5E 1973/4885 |
| US-20100196290-A1 | COMPOSITIONS COMPRISING BETULONIC ACID | BET1, PGGT1B, RABGGTB | GPBAR1 764/4885LMNA 3692/4885NT5E 1111/4885 |
| US-20100273801-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | BET1, CUTA, BECN1 | GPBAR1 1652/4885LMNA 3874/4885NT5E 1606/4885 |
| US-20100190795-A1 | BETULIN DERIVED COMPOUNDS USEFUL AS ANTIPROTOZOAL AGENTS | BET1, BECN1, PGGT1B | GPBAR1 1716/4885LMNA 990/4885NT5E 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.